Perimenopause library · Care

Where the medical and social accounts meet

Updated 2026-08-24 · 2 min read

The medical cohorts and the sociological work are often framed as rivals. Read together, they sharpen the same points.

SWAN empirically confirms what Lock argued from ethnography: vasomotor burden is not uniform across racial and ethnic groups. That finding is biology and social position at once — stress, education, care load, and local biologies, not a single “hot flash gene.”

Sociological work explains why a 7.4-year median still surprises people. Biomedical scripts treat menopause as a short endocrine event. Lived time is long, uncertain, and nested in work and family. Hoga’s qualitative synthesis found clinicians under-attending to what the change means to the person in the room.

Depression risk in the transition is medical (a status effect in SWAN that was independent of measured hormones) and social (life events, support, prior illness). The 2018 guidelines already say screen. They do not say “it is only hormones.”

Hormone-therapy debates sit on top of older medicalization critiques. NAMS describing hormone therapy as effective for bothersome vasomotor symptoms inside a defined window is not the same move as treating midlife itself as a deficiency disease. You can hold both: symptoms can be treated, and the years around the final period are still a social and bodily transition with more than one possible meaning.

For a clinic visit, that translation is practical. Bring the pattern (what, how often, how much it interferes). Bring the context (work, care for others, sleep, prior depression). Ask what can be investigated, what can be treated, and what simply has to be lived through with better information. ClearDay is for the first two lists. It is not the appointment.

Read the product boundary